Spots Global Cancer Trial Database for japan
Every month we try and update this database with for japan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies | NCT02485119 | Neoplasms | BAY94-9343 | 20 Years - | Bayer | |
| A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors | NCT03910530 | Advanced Solid ... Metastatic Soli... | Retifanlimab INCB001158 Retifanlimab + ... | 18 Years - | Incyte Corporation | |
| Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy | NCT04736576 | Breast Cancer | Wearable device | 20 Years - | Pfizer | |
| Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) | NCT05012865 | Renal Cell Carc... | avelumab axitinib | 20 Years - | Pfizer | |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | NCT03006887 | Solid Tumors | lenvatinib pembrolizumab | 20 Years - | Eisai Inc. | |
| Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan | NCT05399329 | Breast Cancer | Palbociclib Endocrine thera... | 20 Years - | Pfizer | |
| Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen | NCT04940065 | Relapsing-remit... Active Secondar... | Kesimpta | - 99 Years | Novartis | |
| Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan | NCT01132625 | Advanced Solid ... | AUY922 | 20 Years - | Novartis | |
| A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | NCT03009344 | Relapsed or Ref... | Tazemetostat | 20 Years - | Eisai Inc. | |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | NCT03006926 | Hepatocellular ... | lenvatinib pembrolizumab (... | 18 Years - | Eisai Inc. | |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | NCT03006926 | Hepatocellular ... | lenvatinib pembrolizumab (... | 18 Years - | Eisai Inc. | |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | NCT03006926 | Hepatocellular ... | lenvatinib pembrolizumab (... | 18 Years - | Eisai Inc. | |
| Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | NCT05650164 | Renal Cell Carc... | avelumab axitinib | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | NCT04593927 | Secondary Progr... | Mayzent | - 99 Years | Novartis | |
| Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients | NCT04593927 | Secondary Progr... | Mayzent | - 99 Years | Novartis | |
| A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan | NCT00503477 | Advanced Solid ... | AZD2171 | 20 Years - 75 Years | AstraZeneca | |
| Factors Associated With High Mortality of Gastric Adenocarcinoma in Thailand Versus Japan | NCT03059732 | Risk Factor | Treatment | 18 Years - | King Chulalongkorn Memorial Hospital | |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | NCT03006887 | Solid Tumors | lenvatinib pembrolizumab | 20 Years - | Eisai Inc. | |
| A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan | NCT00503477 | Advanced Solid ... | AZD2171 | 20 Years - 75 Years | AstraZeneca | |
| Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan | NCT05399329 | Breast Cancer | Palbociclib Endocrine thera... | 20 Years - | Pfizer | |
| Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | NCT05650164 | Renal Cell Carc... | avelumab axitinib | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | NCT03009344 | Relapsed or Ref... | Tazemetostat | 20 Years - | Eisai Inc. | |
| A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread | NCT05431777 | Urothelial Carc... | Avelumab | 0 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan. | NCT02371174 | Breast Cancer HER2-negative B... | - | Eisai Inc. | ||
| Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer | NCT00327119 | Metastatic Colo... | ABX-EGF (panitu... | 20 Years - | Amgen | |
| Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2) | NCT05650164 | Renal Cell Carc... | avelumab axitinib | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
